Cowen, Stifel, Roth Capital and National Securities assist with deal
By Devika Patel
Knoxville, Tenn., July 22 – CymaBay Therapeutics, Inc. priced a $22 million public offering of stock with a $3.3 million greenshoe, according to a prospectus filed Tuesday with the Securities and Exchange Commission. The deal was announced April 8.
The company will sell 4 million common shares at $5.50 apiece. The price per share is a 7.87% discount to the July 21 closing share price of $5.97.
Cowen and Co. and Stifel are the joint bookrunning managers.
Settlement is expected July 25.
Proceeds will be used for product development, working capital, capital expenditures and other general corporate purposes.
The Newark, Calif., company develops therapies to treat metabolic and rare diseases.
| Issuer: | Texas Capital Bancshares, Inc.
|
| Issue: | Common shares
|
| Amount: | $22 million
|
| Greenshoe: | $3.3 million
|
| Shares: | 4 million
|
| Price: | $5.50
|
| Warrants: | No
|
| Bookrunners: | Cowen and Co. and Stifel
|
| Co-managers: | Roth Capital Partners and National Securities Corp.
|
| Announcement date: | April 8
|
| Pricing date: | July 22
|
| Settlement date: | July 25
|
| Stock symbol: | Nasdaq: CBAY
|
| Stock price: | $5.97 at close July 21
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
